1. Scrip
  2. >>New Products

Europe Takes Leap Of Faith On AstraZeneca Vaccine

EU Confirms Approval, Excuses Lack Of Data In Older Groups

 
• By Andrew McConaghie and Neena Brizmohun

A conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine came just hours after the European Medicines Agency’s CHMP voted unanimously to recommend it on Friday.  

Stone / UK - September 9 2020: AstraZeneca vaccine also known as Oxford vaccine. Syringe and AstraZeneca logo on the blurred background. Selective focus. Concept.
AstraZeneca's product will be the third COVID-19 vaccine approved in the EU • Source: Shutterstock

The European Union has granted a conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine, just hours after the European Medicines Agency’s key medicines committee voted unanimously to recommend it – overcoming widespread reservations about a lack of efficacy data in older people.

The decision comes at the end of a torrid week for AstraZeneca, which has found itself in an increasingly public row with the European Commission, which claims the company has broken a binding commitment by lowering its planned vaccine supplies in Q1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.